Takahisa Yamashita

Dr. Takahisa Yamashita

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in The American Journal of Pathology
Verified
Journal Article
Closed access
TYTakahisa Yamashita
Takahisa Yamashita
MHMorihiro Higashi
Morihiro Higashi
HSHironori Sugiyama
Hironori Sugiyama
MMMakoto Morozumi
Makoto Morozumi
SMShuji Momose
Shuji Momose
JTJun-Ichi Tamaru
Jun-Ichi Tamaru

12 February 2025 in Pathology International
Verified
Journal Article
Closed access
TYTakahisa Yamashita
Takahisa Yamashita
MHMorihiro Higashi
Morihiro Higashi
MYMami Yamazaki
Mami Yamazaki
HIHiroki Imada
Hiroki Imada
NTNatsuko Takayanagi
Natsuko Takayanagi
SMShuji Momose
Shuji Momose

25 June 2021 in Pathology International
Verified
Journal Article
Closed access
PDF file
NTNatsuko Takayanagi
Natsuko Takayanagi
SMShuji Momose
Shuji Momose
JKJun Kikuchi
Jun Kikuchi
YTYuka Tanaka
Yuka Tanaka
TATomoe Anan
Tomoe Anan
JTJun‐Ichi Tamaru
Jun‐Ichi Tamaru

1 January 2020 in Journal of Clinical and Experimental Hematopathology
Verified
Journal Article
Open access
PDF file
TYTakahisa Yamashita
Takahisa Yamashita
CVClaudia Vollbrecht
Claudia Vollbrecht
BHBurkhard Hirsch
Burkhard Hirsch
KKKarsten Kleo
Karsten Kleo
IAIoannis Anagnostopoulos
Ioannis Anagnostopoulos
MHMichael Hummel
Michael Hummel
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

12 March 2022 in Journal of Pediatric Surgery Case Reports
Verified
Journal Article
Open access
SISeiichiro Inoue
Seiichiro Inoue
AOAkio Odaka
Akio Odaka
YMYuki Muta
Yuki Muta
SMShohei Maruta
Shohei Maruta
YTYuta Takeuchi
Yuta Takeuchi
TYTakahisa Yamashita
Takahisa Yamashita
We experienced an infant with small bowel intussusception due to a rare pathological lead point. The two-month-old baby has admitted to our center with because of vomiting and bloody stool. Although an intraabdominal multicystic mass was suspected by abdominal ultrasonography, other examinations did not detect any abnormal findings. The infant was discharged but was readmitted one week later because of vomiting and transient impairment of consciousness. Although no ileocolic intussusception was visible by enema, abdominal computed tomography and ultrasonography clearly showed intestinal invagination. Emergency laparotomy was performed, whereupon a small bowel intussusception was observed. After surgical reduction, a small, palpable intramural mass was found at the lead point of the invagination, and the section of the intestine containing the mass was removed by wedge resection. The mass was multicystic and was diagnosed by immunohistochemistry as an intestinal submucosal cyst.

30 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TYTakahisa Yamashita
Takahisa Yamashita
SNShoichi Nagamoto
Shoichi Nagamoto
MAMasahiro Arai
Masahiro Arai
SKSachi Kitayama
Sachi Kitayama
AYAkihiro Yano
Akihiro Yano
MHMorihiro Higashi
Morihiro Higashi
Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings. However, therapeutic efficacy is frequently limited by intrinsic or acquired resistance. Gemcitabine functions as a prodrug whose activity depends on coordinated processes involving cellular uptake, intracellular activation, metabolic inactivation, and nucleotide metabolism. Increasing evidence suggests that resistance in UC is mediated by multiple interconnected mechanisms beyond alterations in gemcitabine transport, activation, and inactivation alone. Key molecular determinants include human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytidine deaminase (CDA), and ribonucleotide reductase regulatory subunit M1 (RRM1), which is involved in nucleotide pool maintenance and DNA synthesis. In addition, replication stress responses, apoptosis evasion pathways, and tumor microenvironment-associated factors also contribute to gemcitabine resistance. Stress-adaptive pathways involving Y-box binding protein 1 (YB-1), hypoxia-inducible factor-1 alpha (HIF-1α), and autophagy-related mechanisms may further promote survival under chemotherapy-induced stress conditions. In addition, extracellular mucin-associated mechanisms may alter intratumoral drug accessibility and contribute to resistance. In this review, we summarize UC-specific evidence regarding gemcitabine resistance and discuss how these pathways collectively shape an integrated resistant phenotype.